Format

Send to

Choose Destination
Monaldi Arch Chest Dis. 2009 Mar;71(1):15-20.

Stromelysin-1 polymorphism as a new potential risk factor in progression of chronic obstructive pulmonary disease.

Author information

1
Institute of Lung Disease, University of Milan, Respiratory Unit, San Paolo Hospital, Milano, Italy.

Abstract

BACKGROUND:

Chronic obstructive lung disease (COPD) is characterised by partially reversible usually progressive airflow limitation caused by inflammation and remodelling. Stromelysin-1 (MMP-3) has regulatory activity on other matrix-metalloproteinases. Altered MMP-3 activity has been described in different diseases. We investigated the role of a promoter MMP-3 polymorphism in determining susceptibility and severity of COPD.

METHODS:

We studied 147 patients with COPD in stable conditions and distinguished two groups based on FEV1 values. In 100 patients functional modifications across a two-year period were noted. 133 healthy subjects were used as controls. Genotyping for the -1171 5A/6A MMP-3 polymorphism was performed using nucleotide sequencing.

RESULTS:

No difference was noted in the genotype distribution between COPD patients and controls. However, among patients with severe disease 6A/6A genotype and 6A allelic frequency were significantly more represented than among mild-moderate patients (p < 0.05). The 6A/6A genotype was also associated with a higher FEV1 decline over time.

CONCLUSIONS:

Our data suggests that -1171 6A allele does not represent a risk factor for the development of COPD while it is associated with more severe disease and different functional decline. We hypothesis that a disregulation of MMP-3, possibly caused by the -1171 5A/6A polymorphism or other linked variants, may lead to different progression in COPD.

PMID:
19522160
DOI:
10.4081/monaldi.2009.371
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center